
CLAIMS

1. An antisense oligomer according to Formula (I):




(I)

or a pharmaceutically acceptable salt thereof, wherein:

each **Nu** is a nucleobase which taken together form a targeting sequence;

T is







and the distal –OH of the T moiety is optionally linked to a cell-penetrating peptide;

R^{100} is hydrogen or a cell-penetrating peptide;


each **Nu** from 5' to 3' corresponds to the nucleobases in:

Annealing Site	Targeting Sequence [5' to 3']	SEQ ID NO:
H50D(+07-16)	GAT CCA GTA TAC TTA CAG GCT CC	SEQ ID NO: 3

wherein A is , C is , G is , and T is .

2. The antisense oligomer of claim 1, wherein the antisense oligomer contains one cell penetrating peptide.

3. The antisense oligomer of claim 1, wherein:

T is ; and


R^{100} is a cell-penetrating peptide.

4. The antisense oligomer of any one of claims 1-3, wherein the cell-penetrating peptide is an arginine-rich peptide, preferably wherein the arginine-rich peptide is selected from the group consisting of $–(RXR)_4-R^a$ (SEQ ID NO: 15), $R-(FFR)_3-R^a$ (SEQ ID NO: 16), -B-X-$(RXR)_4-R^a$ (SEQ ID NO: 17), -B-X-R-$(FFR)_3-R^a$ (SEQ ID NO: 18), -GLY-R-$(FFR)_3-R^a$ (SEQ ID NO: 19), -GLY-R_5-R^a (SEQ ID NO: 20), $–R_5-R^a$ (SEQ ID NO: 21), -GLY-R_6-R^a (SEQ ID NO: 11) and $–R_6-R^a$ (SEQ ID NO: 10), wherein R^a is selected from H, acyl, benzoyl, and stearoyl, and wherein R is arginine, X is 6-aminohexanoic acid, B is β-alanine, F is phenylalanine and GLY (or G) is glycine.

5. The antisense oligomer of any one of claims 1-4, wherein the antisense oligomer is in free base form.

6. The antisense oligomer of any one of claims 1-4, wherein the antisense oligomer is a pharmaceutically acceptable salt thereof.





7. The antisense oligomer of claim 1, wherein the antisense oligomer is of Formula (III):



(III)

or a pharmaceutically acceptable salt thereof, where each **Nu** from 5' to 3' corresponds to the nucleobases in one of the following:


Annealing Site	**Targeting Sequence [5' to 3']**	**SEQ ID NO:**
H50D(+07-16)	GAT CCA GTA TAC TTA CAG GCT CC	SEQ ID NO: 3

wherein A is , C is , G is , and T is ,

and the distal –OH of formula (III) is optionally linked to a cell penetrating peptide.

8. The antisense oligomer of any one of claim 7, wherein the antisense oligomer is in free base form, or wherein the antisense oligomer is a pharmaceutically acceptable salt thereof.





9. The antisense oligomer of claim 1, wherein the antisense oligomer is of Formula (IV):




(IV)

where each **Nu** from 5' to 3' corresponds to the nucleobases in one of the following:

Annealing Site	**Targeting Sequence [5' to 3']**	**SEQ ID NO:**
H50D(+07-16)	GAT CCA GTA TAC TTA CAG GCT CC	SEQ ID NO: 3

wherein A is , C is , G is , and T is  and the distal –OH of formula (IV) is optionally linked to a cell penetrating peptide.

10. The antisense oligomer of claim 9, wherein the antisense oligomer is according to the structure of Formula (IVa)



(IVa).

11. A pharmaceutical composition comprising an antisense oligomer of any one of claims 1-10 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. Use of the antisense oligomer of any one of claims 1 – 10 or the pharmaceutical composition of claim 11 in the manufacture of a medicament for the treatment of Duchenne muscular dystrophy (DMD) in a subject in need thereof.

13. The use of claim 12, wherein the subject has a mutation of the dystrophin gene that is amenable to exon 50 skipping.

14. Use of the antisense oligomer of any one of claims 1 – 10 or the pharmaceutical composition of claim 11 in the manufacture of a medicament for the restoration of an mRNA reading frame to induce dystrophin production in a subject, wherein the subject has a mutation of the dystrophin gene that is amenable to exon 50 skipping.

15. The antisense oligomer of any one of claims 1 – 10 or the pharmaceutical composition of claim 11 for use in therapy.